Rx DRUG DEVELOPMENT - WHY NAFLD

“…financial analysts predict that by 2025, the drug market for NAFLD will be worth $20 billion to $35 billion a year. And so far, no drug has been specifically approved for treating the condition.”

Tocotrienols are strong antioxidants and have anti-fibrotic activity. They distribute preferentially to the liver and there is clinical evidence of efficacy. There are no medicines currently approved for the treatment of NAFLD/NASH. This situation creates an unmet medical need for an effective and well tolerated treatment for NAFLD/NASH.

TOP